{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T08:38:55.978557+00:00","company":{"ticker":"CYDY","cik":1175680,"company_name":"CytoDyn Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"7368d6688712aefd7d3707d83aaf6904d68b67cd","cik":1175680,"ticker":"CYDY","company_name":"CytoDyn Inc.","filed_at":"2026-03-24T23:59:59+00:00","payload":{"action":"amendment","agreement_name":null,"agreement_type":"notes_offering","counterparty":null,"effective_date":"2026-03-24","item_codes_triggered":["1.01"],"value_text":null},"claim":"CytoDyn Inc. amended a notes offering (effective 2026-03-24).","evidence_excerpt":"On March 24, 2026, the Company and the holders of Note 1 and Note 2 (collectively, the “Noteholders”) agreed to extend the maturity date of each of the Notes by 36 months (the “Extension Periods”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-033943","anchor_url":"https://secwatch.observer/filing/0001104659-26-033943#claim-7368d6688712aefd7d3707d83aaf6904d68b67cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465926033943/0001104659-26-033943-index.htm"},{"fact_type":"governance_change","fact_key":"70889826c301252d0f17f343910da1bb2bcfed09","cik":1175680,"ticker":"CYDY","company_name":"CytoDyn Inc.","filed_at":"2025-11-21T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-11-21","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to increase authorized shares of common stock from 1,750,000,000 to 2,250,000,000"},"claim":"CytoDyn Inc.: Amended certificate of incorporation to increase authorized shares of common stock from 1,750,000,000 to 2,250,000,000 (effective 2025-11-21).","evidence_excerpt":"On November 21, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation, increasing the total number of authorized shares of common stock, par value $0.001 per share, from 1,750,000,000 to 2,250,000,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-115056","anchor_url":"https://secwatch.observer/filing/0001104659-25-115056#claim-70889826c301252d0f17f343910da1bb2bcfed09","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465925115056/0001104659-25-115056-index.htm"},{"fact_type":"executive_change","fact_key":"93d6cde4c3","cik":1175680,"ticker":"CYDY","company_name":"CytoDyn Inc.","filed_at":"2025-05-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-15","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Robert E. Hoffman was appointed as Chief Financial Officer at CytoDyn Inc..","evidence_excerpt":"On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-006531","anchor_url":"https://secwatch.observer/filing/0001558370-25-006531#claim-93d6cde4c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837025006531/0001558370-25-006531-index.htm"},{"fact_type":"auditor_change","fact_key":"f8dbed20071e3d7c59be95bb9c0deef8ae1cf662","cik":1175680,"ticker":"CYDY","company_name":"CytoDyn Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"BF Borgers CPA PC","disagreement_text":null,"effective_date":"2024-05-06","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"CytoDyn Inc. dismissed BF Borgers CPA PC as its auditor.","evidence_excerpt":"On May 6, 2024, CytoDyn Inc. (the “Company”), at the direction of the Audit Committee of the Company’s Board of Directors (the “Audit Committee”), dismissed BF Borgers CPA PC (“BF Borgers”) as the Company’s independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-006814","anchor_url":"https://secwatch.observer/filing/0001558370-24-006814#claim-f8dbed20071e3d7c59be95bb9c0deef8ae1cf662","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837024006814/0001558370-24-006814-index.htm"}]}